embricitinib   Click here for help

GtoPdb Ligand ID: 14610

Synonyms: Example 2 [WO2020156271]
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Embricitinib is the INN for a Janus kinase inhibitor with anti-inflammatory and immunosuppressant potential. The chemical structure was obtained from WHO INN Proposed List 135 (July 2026). The same chemical structure is claimed in patent WO2020156271 (Jiangsu Vcare Pharmatech) [1]. The company pipeline declares a single orally bioavailable JAK1 inhibitor named VC005, so this is likely the same as embricitinib.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 4
Rotatable bonds 7
Topological polar surface area 111.85
Molecular weight 366.37
XLogP 0.06
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1C[C@@H](CN(C1)NC2=C(C=NC3=C2C=CN3)C(=O)N)C(=O)NCC(F)F
Isomeric SMILES C1C[C@@H](CN(C1)NC2=C3C=CNC3=NC=C2C(=O)N)C(=O)NCC(F)F
InChI InChI=1S/C16H20F2N6O2/c17-12(18)7-22-16(26)9-2-1-5-24(8-9)23-13-10-3-4-20-15(10)21-6-11(13)14(19)25/h3-4,6,9,12H,1-2,5,7-8H2,(H2,19,25)(H,22,26)(H2,20,21,23)/t9-/m0/s1
InChI Key WOWPHKPPVWFLPO-VIFPVBQESA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
VC005 was progressed as a clinical candidate for the tretament of multiple autoimmune conditions.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06723080 Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis Phase 3 Interventional Jiangsu vcare pharmaceutical technology co., LTD
NCT07172360 Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis. Phase 3 Interventional Jiangsu vcare pharmaceutical technology co., LTD
NCT07592585 Phase III Clinical Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis Phase 3 Interventional Jiangsu vcare pharmaceutical technology co., LTD
NCT07598383 A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis Phase 2 Interventional Jiangsu vcare pharmaceutical technology co., LTD